Pharmaceutical companies could be paid a lump sum to reward them for developing successful new antibiotics under proposals designed to 'delink' the profitability of a new drug from its sales volume and make research and development a viable proposition. The proposals, which aim to make R&D of new antibiotics a more attractive investment for the pharmaceutical industry, are outlined in a report published by the UK's Independent Review of Antimicrobial Resistance on 14 May 2015.
展开▼
